The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

January 14, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In late December 2018, the results of a large head-to-head superiority trial in adults with psoriatic arthritis (PsA) were announced.1 This study was a Phase 3b/4, open-label, randomized, parallel-group, controlled clinical trial, comparing on-label doses of ixekizumab and adalimumab along with use of concomitant conventional disease-modifying antirheumatic drugs (DMARDs).

You Might Also Like
  • Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA
  • Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
Explore This Issue
February 2019
Also By This Author
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

Blinded outcome assessments were used to evaluate the efficacy and safety of ixekizumab compared with adalimumab in PsA patients who were biologic DMARD-naive over a 52-week treatment period. The primary efficacy endpoints were simultaneous achievement of ACR50 and PASI100 response at Week 24. Major secondary endpoints included demonstration of non-inferiority in ACR50 and superiority in PASI100 in ixekizumab-treated patients compared with adalimumab-treated patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients (N=566) could be enrolled in the study if they had active PsA and plaque psoriasis (body surface area involvement of at least 3%) and had an inadequate response to at least one conventional DMARD.

Patients with active PsA were randomized to receive a 160 mg starting dose of ixekizumab followed by 80 mg of ixekizumab every four weeks, or 40 mg of adalimumab every two weeks, for a total of 52 weeks. The primary analysis was conducted at Week 24.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients who met criteria for moderate to severe plaque psoriasis received a 160 mg starting dose of ixekizumab followed by 80 mg of ixekizumab every two weeks from Week 2 to Week 12, and every four weeks thereafter. Or these patients received 80 mg starting doses of adalimumab followed by 40 mg of adalimumab every two weeks beginning one week after the initial dose.

Ixekizumab met the primary endpoint and all major secondary endpoints. The safety profile for ixekizumab was similar to that previously reported, with no new safety signals identified. The manufacturer plans to submit detailed data from this study to scientific meetings and peer-reviewed journals this year.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Eli Lilly and Company. News release: Lilly announces positive top-line results for Taltz (ixekizumab) vs. Humira (adalimumab) in a head-to-head (SPIRIT-H2H) superiority study in patients with active psoriatic arthritis. 2018 Dec 17.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, ixekizumab, PsA, Psoriatic ArthritisIssue: February 2019

You Might Also Like:
  • Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA
  • Clinical Trial of Ixekizumab for Psoriatic Arthritis Shows Positive Results
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
  • EU Approves Marketing for Ixekizumab in Adults with PsA

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)